Literature DB >> 20162565

Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations.

P J Psaltis1, S Paton, F See, A Arthur, S Martin, S Itescu, S G Worthley, S Gronthos, A C W Zannettino.   

Abstract

The cardiovascular therapeutic potential of bone marrow mesenchymal stromal/stem cells (MSC) is largely mediated by paracrine effects. Traditional preparation of MSC has involved plastic adherence-isolation. In contrast, prospective immunoselection aims to improve cell isolation by enriching for mesenchymal precursor cells (MPC) at higher purity. This study compared the biological characteristics and cardiovascular trophic activity of plastic adherence-isolated MSC (PA-MSC) and MPC prepared from the same human donors by immunoselection for stromal precursor antigen-1 (STRO-1). Compared to PA-MSC, STRO-1-MPC displayed greater (1) clonogenicity, (2) proliferative capacity, (3) multilineage differentiation potential, and (4) mRNA expression of mesenchymal stem cell-related transcripts. In vitro assays demonstrated that conditioned medium from STRO-1-MPC had greater paracrine activity than PA-MSC, with respect to cardiac cell proliferation and migration and endothelial cell migration and tube formation. In keeping with this, STRO-1-MPC exhibited higher gene and protein expression of CXCL12 and HGF. Inhibition of these cytokines attenuated endothelial tube formation and cardiac cell proliferation, respectively. Paracrine responses were enhanced by using supernatant from STRO-1(Bright) MPC and diminished with STRO-1(Dim) conditioned medium. Together, these findings indicate that prospective isolation gives rise to mesenchymal progeny that maintain a higher proportion of immature precursor cells compared to traditional plastic adherence-isolation. Enrichment for STRO-1 is also accompanied by increased expression of cardiovascular-relevant cytokines and enhanced trophic activity. Immunoselection thus provides a strategy for improving the cardiovascular reparative potential of mesenchymal cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162565     DOI: 10.1002/jcp.22081

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  55 in total

1.  Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.

Authors:  Carmen Mariana Aanei; Pascale Flandrin; Florin Zugun Eloae; Eugen Carasevici; Denis Guyotat; Eric Wattel; Lydia Campos
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

Review 2.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 3.  Paracrine mechanisms of stem cell reparative and regenerative actions in the heart.

Authors:  Maria Mirotsou; Tilanthi M Jayawardena; Jeffrey Schmeckpeper; Massimiliano Gnecchi; Victor J Dzau
Journal:  J Mol Cell Cardiol       Date:  2010-08-19       Impact factor: 5.000

4.  Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices.

Authors:  Deborah D Ascheim; Annetine C Gelijns; Daniel Goldstein; Lemuel A Moye; Nicholas Smedira; Sangjin Lee; Charles T Klodell; Anita Szady; Michael K Parides; Neal O Jeffries; Donna Skerrett; Doris A Taylor; J Eduardo Rame; Carmelo Milano; Joseph G Rogers; Janine Lynch; Todd Dewey; Eric Eichhorn; Benjamin Sun; David Feldman; Robert Simari; Patrick T O'Gara; Wendy C Taddei-Peters; Marissa A Miller; Yoshifumi Naka; Emilia Bagiella; Eric A Rose; Y Joseph Woo
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

5.  Automated microscopy as a quantitative method to measure differences in adipogenic differentiation in preparations of human mesenchymal stromal cells.

Authors:  Jessica L Lo Surdo; Bryan A Millis; Steven R Bauer
Journal:  Cytotherapy       Date:  2013-08-29       Impact factor: 5.414

6.  Heparan sulfate enhances the self-renewal and therapeutic potential of mesenchymal stem cells from human adult bone marrow.

Authors:  Torben Helledie; Christian Dombrowski; Bina Rai; Zophia X H Lim; Ian Lee Hock Hin; David A Rider; Gary S Stein; Wanjin Hong; Andre J van Wijnen; James H Hui; Victor Nurcombe; Simon M Cool
Journal:  Stem Cells Dev       Date:  2012-01-18       Impact factor: 3.272

Review 7.  The non-coding road towards cardiac regeneration.

Authors:  James E Hudson; Enzo R Porrello
Journal:  J Cardiovasc Transl Res       Date:  2013-12       Impact factor: 4.132

8.  A safe and efficient method to retrieve mesenchymal stem cells from three-dimensional fibrin gels.

Authors:  Bita Carrion; Isaac A Janson; Yen P Kong; Andrew J Putnam
Journal:  Tissue Eng Part C Methods       Date:  2013-08-14       Impact factor: 3.056

9.  Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties.

Authors:  Erin A Kimbrel; Nicholas A Kouris; Gregory J Yavanian; Jianlin Chu; Yu Qin; Ann Chan; Ram P Singh; Deborah McCurdy; Lynn Gordon; Ralph D Levinson; Robert Lanza
Journal:  Stem Cells Dev       Date:  2014-05-02       Impact factor: 3.272

10.  Mesenchymal stem cells improve cardiac conduction by upregulation of connexin 43 through paracrine signaling.

Authors:  Shwetha Mureli; Christopher P Gans; Dan J Bare; David L Geenen; Nalin M Kumar; Kathrin Banach
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.